✦ LIBER ✦

PCN109 Cost Effectiveness of First Line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients: A Markov Model

✍ Scribed by Borget, I.; Vergnenegre, A.; Chouaid, C.

Book ID: 122301588
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 60 KB
Volume: 14
Category: Article
ISSN: 1098-3015
DOI: 10.1016/j.jval.2011.08.1210

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Epidermal growth factor receptor (EGFR)

Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs)

✍ Elena María Martínez-Navarro; Joseba Rebollo; Ramón González-Manzano; Manuel Sur 📂 Article 📅 2011 🏛 Springer Milan 🌐 Spanish ⚖ 230 KB

Do We Really Need Another Epidermal Grow

Do We Really Need Another Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in First-Line Treatment for Patients With Non-Small-Cell Lung Cancer and EGFR Mutations?

✍ Haspinger, E. R.; Garassino, M. C.; Torri, V.; Cinquini, M.; De Braud, F.; Gelso 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 78 KB

PCN63 EPIDERMAL GROWTH FACTOR RECEPTOR (

PCN63 EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION TESTING AND FIRST LINE TREATMENT WITH GEFITINIB IS A DOMINANT STRATEGY IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

✍ G. de Lima Lopes 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

Erlotinib as first-line treatment of Eur

Erlotinib as first-line treatment of European non-small-cell lung cancer (NSCLC) patients (pts.) with epidermal growth factor receptor (EGFR) activating mutations (mut+)

✍ Petruzelka, Lubos 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 43 KB

Pretreatment Epidermal Growth Factor Rec

Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non-Small-Cell Lung Cancer

✍ Su, K.-Y.; Chen, H.-Y.; Li, K.-C.; Kuo, M.-L.; Yang, J. C.-H.; Chan, W.-K.; Ho, 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 676 KB

OP3 Cost-effectiveness of epidermal grow

OP3 Cost-effectiveness of epidermal growth-factor receptor mutation testing and first-line treatment with gefitinib for advanced non-small-cell lung cancer

✍ G. de Lima Lopes; J. Segel; D. Tan; Y. Do; T. Mok; E. Finkelstein 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 34 KB